These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 22333881

  • 1. Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
    Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R, Minucci S, de Thé H.
    Leukemia; 2012 Jul; 26(7):1630-7. PubMed ID: 22333881
    [Abstract] [Full Text] [Related]

  • 2. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Thé H.
    Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
    [Abstract] [Full Text] [Related]

  • 3. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
    Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de Thé H.
    Clin Cancer Res; 2009 Oct 15; 15(20):6321-6. PubMed ID: 19808868
    [Abstract] [Full Text] [Related]

  • 4. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R, de Thé H.
    Int J Hematol; 2010 Jun 15; 91(5):742-7. PubMed ID: 20455087
    [Abstract] [Full Text] [Related]

  • 5. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
    Riccioni R, Saulle E, Militi S, Sposi NM, Gualtiero M, Mauro N, Mancini M, Diverio D, Lo Coco F, Peschle C, Testa U.
    Leukemia; 2003 Jan 15; 17(1):98-113. PubMed ID: 12529666
    [Abstract] [Full Text] [Related]

  • 6. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.
    Duprez E, Wagner K, Koch H, Tenen DG.
    EMBO J; 2003 Nov 03; 22(21):5806-16. PubMed ID: 14592978
    [Abstract] [Full Text] [Related]

  • 7. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W, Wang H, Zhao W, Zhu J, Ju B, Wang X.
    Chin Med J (Engl); 2001 Jan 03; 114(1):30-4. PubMed ID: 11779431
    [Abstract] [Full Text] [Related]

  • 8. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
    Vitaliano-Prunier A, Halftermeyer J, Ablain J, de Reynies A, Peres L, Le Bras M, Metzger D, de Thé H.
    Blood; 2014 Dec 11; 124(25):3772-80. PubMed ID: 25258343
    [Abstract] [Full Text] [Related]

  • 9. A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy.
    Naeem M, Harrison K, Barton K, Nand S, Alkan S.
    Eur J Haematol; 2006 Feb 11; 76(2):164-6. PubMed ID: 16405439
    [Abstract] [Full Text] [Related]

  • 10. Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication.
    Moretti S, Abdel-Aziz AK, Ceccacci E, Pallavicini I, Santoro F, de Thé H, Minucci S.
    Leukemia; 2022 May 11; 36(5):1306-1312. PubMed ID: 35246604
    [Abstract] [Full Text] [Related]

  • 11. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
    Ablain J, Leiva M, Peres L, Fonsart J, Anthony E, de Thé H.
    J Exp Med; 2013 Apr 08; 210(4):647-53. PubMed ID: 23509325
    [Abstract] [Full Text] [Related]

  • 12. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A, Luppi M, Petrini M, Torelli G.
    Haematologica; 1999 Nov 08; 84(11):963-8. PubMed ID: 10553155
    [Abstract] [Full Text] [Related]

  • 13. Combination of all-trans retinoic acid with butyric acid and its prodrugs markedly enhancing differentiation of human acute promyelocytic leukemia NB4 cells.
    Chen Z, Wang W, Pan J, Chen L, Xue Y.
    Chin Med J (Engl); 1999 Apr 08; 112(4):352-5. PubMed ID: 11593538
    [Abstract] [Full Text] [Related]

  • 14. Autophagic degradation of an oncoprotein.
    Bøe SO, Simonsen A.
    Autophagy; 2010 Oct 08; 6(7):964-5. PubMed ID: 20724820
    [Abstract] [Full Text] [Related]

  • 15. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD.
    Leukemia; 2005 Jul 08; 19(7):1161-8. PubMed ID: 15902297
    [Abstract] [Full Text] [Related]

  • 16. Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.
    Puccetti E, Ruthardt M.
    Leukemia; 2004 Jul 08; 18(7):1169-75. PubMed ID: 15103387
    [Abstract] [Full Text] [Related]

  • 17. Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway.
    Huai L, Wang C, Zhang C, Li Q, Chen Y, Jia Y, Li Y, Xing H, Tian Z, Rao Q, Wang M, Wang J.
    Biochem Biophys Res Commun; 2012 Jun 08; 422(3):398-404. PubMed ID: 22575507
    [Abstract] [Full Text] [Related]

  • 18. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V, Zhu J, Chen Z, de Thé H.
    Trends Mol Med; 2012 Jan 08; 18(1):36-42. PubMed ID: 22056243
    [Abstract] [Full Text] [Related]

  • 19. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.
    Esnault C, Rahmé R, Rice KL, Berthier C, Gaillard C, Quentin S, Maubert AL, Kogan S, de Thé H.
    Blood; 2019 Mar 28; 133(13):1495-1506. PubMed ID: 30674471
    [Abstract] [Full Text] [Related]

  • 20. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D, Mistry AR, Solomon E, Guidez F.
    Cancer Treat Res; 2010 Mar 28; 145():219-35. PubMed ID: 20306254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.